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Abstract
Background: The Patient Protection and Affordable Care Act (ACA) galvanised debate in the United States (US) over
universal health coverage. Comparison with countries providing universal coverage may illustrate whether the ACA can
improve health outcomes and reduce disparities. We aimed to compare quality and disparities in hypertension
management by socio-economic position in the US and England, the latter of which has universal health care.
Method:We used data from the Health and Retirement Survey in the US, and the English Longitudinal Study for Aging from
England, including non-Hispanic White respondents aged 50–64 years (US market-based v NHS) and .65 years (US-
Medicare v NHS) with diagnosed hypertension. We compared blood pressure control to clinical guideline (140/90 mmHg)
and audit (150/90 mmHg) targets; mean systolic and diastolic blood pressure and antihypertensive prescribing, and
disparities in each by educational attainment, income and wealth, using regression models.
Results: There were no significant differences in aggregate achievement of clinical targets aged 50 to 65 years (US market-
based vs. NHS- 62.3% vs. 61.3% [p = 0.835]). There was, however, greater control in the US in patients aged 65 years and over
(US Medicare vs. NHS- 53.5% vs. 58.2% [p = 0.043]). England had no significant socioeconomic disparity in blood pressure
control (60.9% vs. 63.5% [p= 0.588], high and low wealth aged$65 years). The US had socioeconomic differences in the 50–
64 years group (71.7% vs. 55.2% [p = 0.003], high and low wealth); these were attenuated but not abolished in Medicare
beneficiaries.
Conclusion: Moves towards universal health coverage in the US may reduce disparities in hypertension management. The
current situation, providing universal coverage for residents aged 65 years and over, may not be sufficient for equality in
care.
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Introduction
Given the growing global burden of chronic diseases, effective
and equitable management of diseases such as hypertension is a
core requirement of any health system [1]. Despite population
level reductions in blood pressure and improvements in anti-
hypertensive prescribing [2,3],_ENREF_2 suboptimal hyperten-
sion management – most notably insufficient blood pressure
control – persists in many countries, including the United States
(US) and England. One marker of this quality gap across all
countries is within-country disparities in hypertension manage-
ment, which are likely due to population, health care provider and
health system characteristics [4].
Cross-country analysis can examine relationships between
health system structures and outcomes [5,6]. England and the
US have four important differences that may influence hyperten-
sion management. Firstly, the US has a more specialised health
service (higher ratio of specialists to generalists; more ambulatory
care delivered by specialists) whereas the National Health Service
(NHS) emphasizes generalist primary care, with restricted access to
specialists through gate-keeping. Strong primary care can improve
health outcomes [7,8] and may reduce inequalities [7], especially
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in conditions requiring longitudinal care such as hypertension [9].
Second, as a single payer system, the NHS arguably has clearer
lines of accountability and more centralized coordination of
quality improvement (though the more pluralistic US system may
be more innovative). Thirdly, the US has considerably higher
health care spending than England; although this may be
considered a result of other structural differences [10]. In 2009
the US spent 17.4 percent of its Gross Domestic Product on health
care, compared with 9.8 percent in the United Kingdom (UK).
This may provide resources for higher quality care, although the
relationship between health care spending and quality remains
unclear [10].
Finally, England offers universal health coverage with care free
at the point of delivery. Medication in England costs a standard
prescription charge (£7.10 (,$13.90) in April 2008), although
exemptions mean that approximately 60 percent of the popula-
tion, and 90 percent of items dispensed are free of charge [11].
Exempt groups include people aged 60 years and over, people on
income support, or those with certain chronic health conditions –
although not hypertension. The US has universal coverage for
people aged 65 years and over, through Medicare. Co-payments
for medications, however, remain high, despite Medicare’s ‘‘Part
D’’ drug prescription benefit program [12]. Health coverage for
younger US patients is more variable, with a high proportion
without insurance or under-insured [4]. Having survived legal
contests over the ‘‘individual mandate’’ and given the outcome of
the 2012 presidential election, the Patient Protection and
Affordable Care Act (ACA) will partly address this. It will expand
Medicaid eligibility and enhance individual access to private
health insurance, although the former may be limited by the
power of individual states not to implement changes [13].
We aim to determine whether health system differences
between the US and England influence the quality of hypertension
management and disparities across socio-economic position (SEP),
characterised by income, wealth and education [14]. By stratifying
respondents into one group younger than 65 years and the other
older (i.e. the eligibility criteria for Medicare), we compare
hypertension management in the NHS both with part of the US
health care system with universal (Medicare) coverage and with
the market-based system for those under 65. The latter will see
coverage expanded as part of the ACA.
Materials and Methods
Data Sources
We analysed data from two national longitudinal surveys, the
English Longitudinal Study of Aging (ELSA), and the Health and
Retirement Survey (HRS) from the US. These provide compara-
ble data on aging, with similar sampling techniques and content
[5]. Both are population-based surveys presenting information on
health, physical and mental functioning, demographic factors,
behaviors and SEP in non-institutionalized individuals aged 50
years and over.
ELSA, a biennial survey, began in 2002, sampling respondents
aged 50 years and over [15]. A refreshment sample, aged 50 to 53
years, was added in 2006 to boost representation of younger age
groups. Interviews are carried out at respondents’ homes, with
visiting nurses collecting biomedical data during alternate waves.
The HRS started in 1991 [16], with biennial follow-up since 1992
and subsequent refreshment samples. The HRS has maintained a
sample of more than 20,000 respondents, and is conducted using
both telephone and face-to-face interviews – dependent on the
survey wave and module of questions. Further details of both
surveys can be found elsewhere [15,16].
Study sample
We used data from Wave 4 of ELSA, conducted during 2008
and 2009, which contained 11,050 respondents (response rate
74.3%). We included respondents aged 50 years and over, with
valid blood pressure readings (the mean of two or more readings
on the same day_ these are considered valid for both surveys) from
the survey nurse visit (n = 7,982). To control for differences in
ethnic mix between samples, and ensure that we compared
differences between health systems – not biological differences in
control between samples, we restricted analyses to non-Hispanic
Whites (excluding 225 from ELSA). We exclude respondents with
missing SEP (n= 2,795) and clinical data (body mass index (BMI),
co-morbidities and smoking status; n = 900 – latter two not
mutually exclusive), leaving 4,910 respondents.
For comparison we used data from Wave 9 of the HRS,
administered in 2008, with 17,217 respondents (response rate
88.6%). We include respondents aged 50 years and over, with
valid blood pressure readings (mean of two of more – n=8,273).
We excluded 3,049 non-white and Hispanic respondents, 304 with
no BMI record (there were no missing SEP data), leaving 4,920
respondents.
From the samples defined above, we include respondents with a
self-reported physician’s diagnosis of hypertension, leaving 2,318
ELSA and 2,855 HRS respondents. Both surveys included a
question similar to ‘‘Has a doctor ever told you that you have
hypertension?’’ Though this method may underestimate hyperten-
sion rates compared with measures based on actual blood pressure
values [5], we felt it a more relevant definition for our study, which
relates to the management of patients with a known diagnosis –
further there is no evidence of inequalities in reporting-bias [15].
Predictor variables – measures of SEP
We used three measures of SEP that are comparable between
countries: education, household income and wealth. We divided
education into three groups defined using years of continuous
education; in England 0–11 years, 12–13 and $14; in the USA 0–
12, 13–15 and $16 years. These cut-offs are widely used [5,6],
producing similar education distributions across countries. We
used total household income, and total household wealth (savings,
net stock value, mutual funds, bonds, real estate value, own
business share, owned cars minus liabilities), adjusted for
household size (the square root of household size), and producing
groups separated by tertiles within each country.
Outcome variables
We used mean systolic and diastolic blood pressure (from two or
more measures), defined controlled hypertension as blood pressure
lower than 140/90 mmHg, in line with clinical guidelines [17,18]
and measured prescribing of anti-hypertensive agents based on
self-report. In addition to the guideline-derived target, we assessed
control (in both countries) based on the UK’s audit target of 150/
90 mmHg. This defines control in England’s Quality and
Outcome Framework (QOF), which provides pay-for-performance
remuneration to primary care practices for the management of
chronic disease, including hypertension, therefore is an important
UK threshold for control [19].
Covariates
We controlled for the following potentially confounding
variables: age and sex of respondents; smoking status (current/
non-smoker); BMI; and concordant vascular co-morbidities. All
except BMI were self-reported, which was recorded by study
nurses. We defined the latter as the sum of patient reported doctor
Health Insurance Coverage and Hypertension Control
PLOS ONE | www.plosone.org 2 January 2014 | Volume 9 | Issue 1 | e83705
diagnoses out of coronary heart disease, stroke/transient ischaemic
attack, diabetes or chronic kidney disease.
Statistical Methods
We conducted analyses separately in the groups aged 50 to 64
years and 65 years and over. We present the prevalence of
hypertension, standardized for age and sex, along with summaries
of covariates across indicators of SEP (education, income and
wealth), in patients with hypertension in each country, testing for
statistical significance.
In patients with hypertension, we modelled blood pressure
control (to clinical and audit targets) and anti-hypertensive
medication using logistic regression [20]; and systolic and diastolic
blood pressure using linear regression. We modelled outcomes
separately in each country, age group and individual measure of
SEP; adjusting for age, sex, smoking status, vascular co-morbidity
and BMI. In the 50 to 64 years age group in the US, we present
results in the whole population and the insured group alone. We
defined the insured group as those reporting any health insurance
coverage (private, Medicaid or other health care plan) at the time
of interview. We present adjusted outcomes after recombination of
model coefficient [20], presenting the overal control in each
country and in each SEP group. We test statistical significance in
global control between countries; between SEP groups within each
country, comparing medium and high, with lowest group for each
indicator; and in equivalent SEP groups between countries. We
derived standard errors using the delta method for all adjusted
coefficiants [21]; when unable to estimate variance directly, this
allows accurate estimation [21]. We use valid survey weights in all
analyses (variables w4nurwt in ELSA and lwgtr in the HRS), which
we conducted using Stata 11.2SE.
Results
The unadjusted prevalence of hypertension in England and the
US was 38.2% and 45.1% in respondents aged 50–64 years and
52.9% and 63.6% in those aged.65 years, respectively. There are
significant disparities in prevalence, especially by education and
wealth, which were greatest in US respondents aged 50–64 years.
The characteristics of respondents with hypertension are presented
in table 1. In both age groups, there was higher mean BMI and
prevalence of vascular co-morbidity in the US. There are marked
gradients in smoking in both countries, with a higher prevalence in
lowest SEP groups and, in younger patients, higher BMI in lowest
SEP groups. There are significant SEP disparities in insurance
coverage in US respondents aged 50–64 years.
US Medicare v English NHS (. 65 years)
There was significantly higher aggregate blood pressure (BP)
control in US respondents aged .65 years using clinical
(BP,140/90 mm Hg- 53.5% England vs. 58.2% in US;
p= 0.043) but not audit targets (BP,150/90 mm Hg- 71.9% vs.
73.9% respectively; p = 0.338) (table 2). Mean systolic BP was
significantly lower in the US than England (135.6 vs. 140.2 mm
Hg; p,0.001) but the converse for mean diastolic BP (78.9 vs.
73.7 mm Hg; p,0.001). Prescribing of at least one anti-
hypertensive medication was significantly more common in the
US than England (91.4% vs. 80.9%; p,0.001).
The lowest SEP groups had poorer control to clinical targets in
the US, which reached statistical significance for income (56.3% in
low income vs. 62.9% in high; p = 0.033), but not in England
(table 3). There were no statistically significant SEP disparities to
audit targets. When the analysis compared equivalent SEP groups
between countries (results not presented), the largest disparity in
blood pressure control was present in highest SEP groups (e.g.
income – lowest 53.9% in England vs. 56.3% in US, p= 0.533;
highest 51.0% vs. 62.9% respectively, p = 0.033).
There was higher prescribing of anti-hypertensive medication in
the US across all SEP groups compared with England. In England
there was no SEP disparity in prescribing, whereas the US had
lower prescribing in lowest SEP groups, which was statistically
significant for wealth (87.4% in the least wealthy vs. 92.4% in the
most; p = 0.029).
US Market-based v English NHS (50–64 years)
In patients with hypertension aged 50–64 years, there were no
significant differences in the control of blood pressure to 140/
90 mm Hg between countries (table 2). Respondents with health
insurance in the US had similar control to those in England (61.3
in England vs. 62.3 in all Americans (p = 0.835 vs. England) and
65.4% in the insured (p = 0.409 vs. England). Similarly there were
no statistically significant differences in control to audit targets in
the whole population (74.5 in England vs. 69.4 in the US;
p= 0.255), or insured Americans (72.7; p= 0.695).
Despite no overall difference between countries in the 50–64
years age group, Americans in the highest wealth groups had
significantly better control to the clinical target than their English
counterparts (table 4) (71.7 vs. 60.9; p = 0.037). Wealth disparities
to both clinical and audit targets were present in the US, with
wealthier patients more likely to meet targets, but not in England
(clinical target- 60.9% for wealthy vs. 63.5% for poorer patients in
England (p= 0.588); compared with 71.7% vs. 55.2% (p= 0.003)
in the US). The wealth disparity is reduced, but still significant in
the insured, under-65 American group (72.5 in the most wealthy
vs. 60.7 in the least (p = 0.036)). There was a suggestion of an
income disparity in the US sample, with the intermediate group
having better control than the lowest (clinical target – 54.9% in
low income vs. 66.6% in intermediate (p = 0.05)). This was not,
however statistically significant for the highest income (62.2%;
p= 0.198). There were no income disparities in the English
sample.
Mean systolic blood pressure was lower in the total and insured
American groups aged under 65 years compared with the sample
from England (England= 135.5; insured American= 129.9
(p,0.001 vs. England); total American= 131.2 (p = 0.007 vs.
England)): Diastolic blood pressure was lower in the English
sample, compared with both from the US (England= 81.5; insured
American= 83.9 (p,0.016 vs. England); total American= 84.8
(p,0.001 vs. England)).
English patients with hypertension were less often prescribed
anti-hypertensive medication than insured Americans and Amer-
icans in total (56.4%, 84.2% (p,0.001 vs. England) and 80.2%
(p,0.001 vs. England), respectively). There were no SEP
disparities in prescribing in the US Sample, but there was
statistically significantly lower prescribing in the lowest wealth
group in the total US sample compared with the lowest (71.2% in
lowest vs. 86.0% in the highest; p = 0.004). There were no
prescribing disparities in the US sample reporting health
insurance.
Discussion
Main findings
Patients with hypertension in America eligible for Medicare are,
overall, more likely than their English counterparts to have their
blood pressure controlled to the clinical guideline target, but not to
the English audit target. Patients aged 50 to 64 years, with
insurance coverage through the NHS or under the market-based
Health Insurance Coverage and Hypertension Control
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Table 1. Risk factors and characteristics in hypertensive patients aged greater than 50 years in England and the United States.
England United States
Years of education
Low Medium High Total Low Medium High Total
Age 50 to 64 years
N hypertensive¤ 451 63 212 726 340 164 164 668
Prevalence, % (SE) 35.9 (2.2) 30.2 (3.5) 30.1 (2.2) 33.4 (1.8) 47.3 (2.4)` 43 (2.9)` 33.4 (2.6) 41.7 (1.7)`
Sex (% Female, SE)¤ 54.0 (2.4) 39.9 (6.1) 40.0 (3.3) 49.3 (1.9) 48.5 (3.8) 38.1 (5.1) 35.6 (5.3) 42.8 (2.7)
Age, mean (SE)¤ 60.3 (0.1) 59.7 (0.3) 59.9 (0.2) 60.1 (0.1) 59.2 (0.2) 59.1 (0.3) 59.2 (0.3) 59.2 (0.2)
Current smoker, % (SE) 20.5 (2.0) 12.6 (4.4) 8.2 (2.2) 16.7 (1.5) 25.0 (2.7) 19.3 (3.5) 11.6 (3.0) 20.0 (1.8)
BMI mean (SE) 30.6 (0.3) 29.9 (0.7) 29.3 (0.3) 30.2 (0.2) 31.5 (0.5) 31.9 (0.7)` 30.7 (0.7) 31.4 (0.3)`
.1 Vascular Co Morb, % (SE) 17.3 (1.8) 20.5 (5.2) 12.1 (2.2) 16.2 (1.4) 38.4 (3.7)` 27.9 (4.9)` 20.4 (4.8)` 31.4 (2.5)`
Insurance coverage, % (SE) 86.0 (2.6) 94.2 (2.4) 96.0 (2.5) 90.5 (1.6)
Age$65 years
N hypertensive¤ 1195 68 329 1592 1344 416 427 2187
Prevalence, % (SE) 55.0 (1.1) 46.1 (4.1) 48.4 (1.9) 53.4 (0.9) 65.2 (1.2)` 61.7 (2.1)` 58.9 (2.0)` 63.1 (0.9)`
Sex (% Female, SE)¤ 61.3 (1.4) 43.3 (6.0) 39.3 (2.7) 57.2 (1.3) 54.3 (1.9) 51.6 (3.4) 33.3 (3.1) 49.7 (1.5)
Age, mean (SE)¤ 76.6 (0.2) 75.3 (1.0) 74.3 (0. 5) 76.2 (0.2) 74.8 (0.3) 73.7 (0.5) 74.0 (0. 5) 74.4 (0.2)
Current smoker, % (SE) 10.3 (0.9) 4.7 (2.7) 5.2 (1.2) 9.3 (0.8) 11.1 (0.9) 9.6 (1.8) 5.0 (1.2) 9.6 (0.7)
BMI mean (SE) 28.9 (0.2) 29.2 (0.8) 28.2 (0.3) 28.8 (0.1) 29.8 (0.2)` 29.8 (0.5) 29.2 (0.3)` 29.7 (0.2)`
.1 Vascular Co Morb, % (SE) 27.5 (1.3) 33.4 (5.7) 24.9 (2.4) 27.3 (1.1) 41.1 (1.9)` 35.0 (3.2) 31.6 (3.1)` 38.0 (1.4)`
Income
Low Medium High Total Low Medium High Total
Age 50 to 64 years
N hypertensive¤ 184 250 292 726 161 196 311 668
Prevalence, % (SE) 37.7 (2.8) 35.2 (2.5) 30.1 (2.0) 33.4 (1.8) 47.8 (3.4)` 45.2 (3.0)` 38.1 (2.1)` 41.7 (1.7)`
Sex (% Female, SE)¤ 51.6 (3.8) 49.7 (3.2) 47.2 (2.9) 49.3 (1.9) 53.1 (5.5) 47.1 (5.1) 34.5 (3.7) 42.8 (2.7)
Age, mean (SE)¤ 60.1 (0.2) 60.4 (0.2) 60.0 (0.2) 60.1 (0.1) 59.0 (0.3) 59.2 (0.3) 59.3 (0.2) 59.2 (0.2)
Current smoker, % (SE) 23.7 (3.3) 18.4 (2.6) 10.1 (1.9) 16.7 (1.5) 29.0 (4.1) 24.0 (3.5) 13.6 (2.2) 20.0 (1.8)
BMI mean (SE) 31.2 (0.5) 30.2 (0.4) 29.6 (0.3) 30.2 (0.2) 32.3 (0.7) 31.6 (0.7)` 30.9 (0.5) 31.4 (0.3)`
.1 Vascular Co Morb, % (SE) 23.2 (3.2) 16.9 (2.4) 10.5 (1.8) 16.2 (1.4) 53.3 (5.4)` 24.0 (4.4)` 23.7 (3.4)` 31.4 (2.5)`
Insurance coverage, % (SE) 75.3 (4.7) 94.0 (2.2) 96.8 (1.4) 90.5 (1.6)
Age$65 years
N hypertensive¤ 626 633 333 1592 762 856 569 2187
Prevalence, % (SE) 54.8 (1.5) 54.3 (1.5) 49.0 (1.9) 53.4 (0.9) 68.5 (1.6)` 63.2 (1.4)` 57.2 (1.7)` 63.1 (0.9)`
Sex (% Female, SE)¤ 64.8 (1.9) 53.6 (2.0) 47.1 (2.8) 57.2 (1.3) 55.4 (2.6) 50.3 (2.3) 41.6 (2.8) 49.7 (1.5)
Age, mean (SE)¤ 77.5 (0.3) 75.9 (0.3) 74.0 (0.4) 76.2 (0.2) 74.9 (0.4) 74.3 (0.3) 73.9 (0.4) 74.4 (0.2)
Current smoker, % (SE) 10.1 (1.2) 9.9 (1.2) 6.0 (1.3) 9.3 (0.8) 12.9 (1.4) 9.5 (1.1) 5.3 (1.0) 9.6 (0.7)
BMI mean (SE) 28.6 (0.2) 28.9 (0.2) 29.0 (0.3) 28.8 (0.1) 29.1 (0.3)` 30.1 (0.3)` 29.6 (0.3) 29.7 (0.2)`
.1 Vascular Co Morb, % (SE) 26.7 (1.8) 28.5 (1.8) 26.1 (2.5) 27.3 (1.1) 47.4 (2.6)` 36.0 (2.2)` 29.4 (2.6) 38.0 (1.4)`
Wealth
Low Medium High Total Low Medium High Total
Age 50 to 64 years
N hypertensive¤ 243 224 259 726 237 225 206 668
Prevalence, % (SE) 43.3 (2.7) 31.0 (2.3) 28.1 (2.1) 33.4 (1.8) 53.1 (2.9)` 42.2 (2.6)` 32.1 (2.4) 41.7 (1.7)`
Sex (% Female, SE)¤ 48.2 (3.2) 53.8 (3.4) 46.2 (3.2) 49.3 (1.9) 48.1 (4.5) 41.7 (4.7) 37.2 (4.6) 42.8 (2.7)
Age, mean (SE)¤ 60.1 (0.2) 60.2 (0.2) 60.1 (0.2) 60.1 (0.1) 58.9 (0.3) 59.1 (0.3) 59.6 (0.3) 59.2 (0.2)
Current smoker, % (SE) 27.3 (2.9) 13.9 (2.4) 7.5 (1.8) 16.7 (1.5) 30.0 (3.4) 18.8 (3.0) 10.1 (2.4) 20.0 (1.8)
BMI mean (SE) 31.4 (0.4) 30.0 (0.3) 29.2 (0.3) 30.2 (0.2) 32.1 (0.6) 31.8 (0.5) 30.3 (0.5) 31.4 (0.3)`
.1 Vascular Co Morb, % (SE) 24.4 (2.8) 13.1 (2.2) 10.0 (1.9) 16.2 (1.4) 44.9 (4.4)` 23.6 (4.1)` 22.6 (4.2)` 31.4 (2.5)`
Insurance coverage, % (SE) 83.5 (3.3) 91.9 (2.6) 97.7 (1.6) 90.5 (1.6)
Health Insurance Coverage and Hypertension Control
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US health system, have similar control to both targets, even
limiting the comparison to US patients reporting health insurance.
The US has significantly more prescribing of anti-hypertensive
medication across all levels of SEP. We found no evidence of
disparities in English patients, while significant wealth and income
disparities in blood pressure control and prescribing among
younger US patients. Disparities in both were generally attenuated
but not abolished in insured patients aged under-65 and older
patients eligible for Medicare.
The US is enacting some of its most significant health care
reforms since the formation of Medicare in 1965 [22]. Currently,
up to 46 million Americans are uninsured [22], with gaps in health
insurance estimated to account for up to 45,000 deaths per year
[23]. The ACA aims to extend health insurance coverage to an
additional 31 million citizens. An open question is whether access
to health insurance will improve disease management and reduce
health disparities.
While health insurance may reduce health disparities through
improved access to care, the US and UK health systems differ in
other ways. Primary care plays a significantly greater role in
England, which itself may reduce disparities [7,24]. Importantly,
we not only saw reduced disparities in England compared with the
US, but also in American patients eligible for Medicare compared
with younger patients in the US. Insurance coverage may be a
significant driver of disparities in hypertension control in younger
Americans. In the US, younger patients with market-based (often
private) insurance may trade insurance source (switching to the
Medicare) once eligible. Younger patients lacking insurance
(usually from a lower SEP) are more likely to become newly
eligible for insurance at the age of 65 years [25] and in turn see
greatest increases in health care expenditure [26]. This might, in
part, reduce US disparities in hypertension management.
That said, disparities in blood pressure control are absent in
older English patients but some remain in Medicare-eligible
Americans (for example an income disparity to clinical blood
pressure targets). Universal coverage alone may not eliminate
disparities. The strength of English primary care may increase
equity in hypertension control [7]. Also, in the US, even Medicare
patients, and many with private insurance, face significant co-
payments. These may stop patients obtaining necessary care,
including office visits and pharmaceuticals. Up to 40 percent of
patients with chronic conditions in the US report significant out-
of-pocket payments (.$1,000), compared with only 4 percent in
the UK [27]. Moves under the ACA not only to extend health
insurance but also to impose minimum quality standards on all
policies, including ending annual claims limits and eliminating
certain co-payments, may limit obstacles to appropriate care for
Americans, and improve equity in care [13]. Alternately,
inequalities formed under the age of 65 years may simply become
too entrenched to be fully eradicated under Medicare. SEP may
be a fundamental cause of raised blood pressure [28]; however, health
systems should still seek to provide equitable management for
those with diagnosed hypertension [29].
In addition to more equitable care, the NHS matches the US in
absolute levels of blood pressure control in the sample aged 50 to
64 years. Given greater health care spending in the US [10], this
may suggest more efficient hypertension management under the
NHS than in a US system with no mandated health insurance
Reasons for this may include increased access to primary care, less
overcharging, less duplication of care, less overuse and lower
transaction/overhead costs [10,30]. Moreover, in the US system,
patients – even those with health insurance – are considerably
more likely to forgo necessary care due to cost and less likely to
have a long-term relationship with a health care provider [27].
Patients in the US eligible for Medicare do, however, see better
control, than the sample aged $65 years under the NHS. This
supports previous findings of greater blood pressure control in
patients with hypertension in the US than in England [31]. The
US may have improved treatment strategies, including the
medication use seen here. Systolic blood pressure was lower in
the US sample, but diastolic blood pressure significantly lower in
England (up to a 5 mm. Hg. difference aged $65). Diastolic blood
pressure may be more easily controlled with medication than
systolic blood pressure [32].
One interesting finding is that anti-hypertensive medications are
more far more frequently prescribed in the US sample aged 50 to
64 years, but control remains comparable. The control of blood
pressure in hypertensive patients is not solely determined by the
prescribing of pharmacological agents per se. Other factors,
including use of appropriate combination therapy and life-style
interventions, are important [33]. This might, at least in part,
explain the lack of association between prescribing rates and blood
Table 1. Cont.
England United States
Years of education
Low Medium High Total Low Medium High Total
Age$65 years
N hypertensive¤ 513 594 485 1592 586 778 823 2187
Prevalence, % (SE) 58.4 (1.7) 54.1 (1.5) 47.4 (1.6) 53.4 (0.9) 67.8 (1.8)` 65.2 (1.5)` 58.7 (1.4)` 63.1 (0.9)`
Sex (% Female, SE)¤ 62.6 (2.2) 57.1 (2.0) 50.0 (2.3) 57.2 (1.3) 61.1 (2.8) 47.6 (2.5) 43.4 (2.3) 49.7 (1.5)
Age, mean (SE)¤ 77.2 (0.4) 76.1 (0.4) 75.1 (0.4) 76.2 (0.2) 74.5 (0.4) 74.3 (0.4) 74.4 (0.3) 74.4 (0.2)
Current smoker, % (SE) 15.3 (1.6) 6.5 (1.0) 5.1 (1.1) 9.3 (0.8) 14.8 (1.6) 9.8 (1.2) 5.7 (1.0) 9.6 (0.7)
BMI mean (SE) 29.1 (0.2) 29.0 (0.2) 28.0 (0.2) 28.8 (0.1) 29.4 (0.4) 29.9 (0.3)` 29.6 (0.3)` 29.7 (0.2)`
.1 Vascular Co Morb, % (SE) 34.1 (2.1) 26.0 (1.8) 19.8 (1.9) 27.3 (1.1) 47.2 (2.9)` 38.7 (2.5)` 30.9 (2.2)` 38.0 (1.4)`
BMI = Body Mass Index; BP = Blood Pressure; SE = standard error; Co Morb = co-morbidity; Age controlled to 57 in former age group and 75 in latter.
¤Not tested for statistical significance controlling for age and sex.
{p,0.05.
`p,0.01 testing the English against the US, controlling for age and sex.
doi:10.1371/journal.pone.0083705.t001
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Table 2. Aggregate blood pressure control and prescribing in hypertensive patients aged 50- 64 in the United States and
England.
England United States
Total Total Insured
Aged $65 yearsa Systolic BP mean (SE) 140.2 (0.65) 135.6 (0.64)` –
Diastolic BP mean (SE) 73.7 (0.36) 78.9 (0.34)` –
BP ,140/90 mmHg, % (SE) 53.5 (1.73) 58.2 (1.54){ –
BP ,150/90 mmHg, % (SE) 71.9 (1.55) 73.9 (1.39) –
Anti-hypertensive medication, % (SE) 80.9 (1.34) 91.4 (0.91)` –
Aged 50-64 yearsb Systolic BP mean (SE) 135.5 (1.17) 131.2 (1.05)` 129.9 (1.09)`
Diastolic BP mean (SE) 81.5 (0.70) 84.8 (0.68)` 83.9 (0.68){
BP ,140/90 mmHg, % (SE) 61.3 (3.55) 62.3 (3.15) 65.4 (3.33)
BP ,150/90 mmHg, % (SE) 74.5 (3.24) 69.4 (3.06) 72.7 (3.15)
Anti-hypertensive medication, % (SE) 56.4 (3.71) 80.2 (2.61)` 84.2 (2.56)`
{p,0.05.
`p,0.01 testing US groups against the English total.
aUS Medicare v English NHS group.
bUS market-based v English NHS; BP = Blood Pressure; SE = standard error.
All values and significance testing controls for age and sex, BMI, vascular co-morbidity and smoking (age controlled at 75 & 57 respectively, female sex, non-smoker, no
co-morbidity and BMI = 28.8 – the English mean).
doi:10.1371/journal.pone.0083705.t002
Table 3. Blood pressure control and prescribing in hypertensive patients in US Medicare v English NHS by socioeconomic-position
(. 65 years).
England United States
Years of Education
Low Medium High Low Medium High
Systolic BP mean (SE) 140.1 (0.73) 142.1 (3.00) 140.0 (1.11) 136.7 (0.78) 133.9 (1.24){ 134.6 (1.05)
Diastolic BP mean (SE) 73.4 (0.41) 75.6 (1.44) 74.8 (0.64){ 79.0 (0.42) 78.3 (0.65) 79.4 (0.57)
BP ,140/90 mmHg, % (SE) 53.6 (1.94) 47.8 (6.30) 54.2 (3.03) 56.8 (1.90) 57.9 (2.83) 61.5 (2.67)
BP ,150/90 mmHg, % (SE) 71.8 (1.76) 66.6 (6.20) 73.1 (2.79) 72.8 (1.71) 73.6 (2.51) 76.5 (2.35)
Anti-hypertensive medication, % (SE) 81.0 (1.48) 80.0 (5.16) 80.3 (2.45) 90.3 (1.21) 92.7 (1.87) 92.8 (1.54)
Income
Low Medium High Low Medium High
Systolic BP mean (SE) 139.9 (0.96) 139.9 (0.89) 141.1 (1.16) 136.8 (1.10) 136.3 (0.86) 133.7 (0.94){
Diastolic BP mean (SE) 73.4 (0.53) 73.7 (0.51) 74.4 (0.63) 79.6 (0.58) 78.7 (0.47) 78.6 (0.50)
BP ,140/90 mmHg, % (SE) 53.9 (2.49) 54.5 (2.37) 51.0 (3.04) 56.3 (2.43) 55.8 (2.12) 62.9 (2.29){
BP ,150/90 mmHg, % (SE) 72.0 (2.27) 74.3 (2.11) 67.2 (2.89) 72.4 (2.20) 71.9 (1.95) 77.5 (1.96)
Anti-hypertensive medication, % (SE) 81.7 (1.88) 80.5 (1.80) 79.9 (2.48) 89.6 (1.88) 92.7 (1.10) 91.4 (1.46)
Wealth
Low Medium High Low Medium High
Systolic BP mean (SE) 141.1 (1.10) 139.4 (0.94) 140.3 (0.93) 135.4 (1.21) 137.0 (0.93) 134.7 (0.82)
Diastolic BP mean (SE) 73.1 (0.62) 73.7 (0.52) 74.3 (0.52) 79.1 (0.65) 79.1 (0.50) 78.8 (0.45)
BP ,140/90 mmHg, % (SE) 51.2 (2.87) 55.4 (2.41) 53.1 (2.50) 56.6 (2.76) 56.3 (2.21) 60.3 (1.99)
BP ,150/90 mmHg, % (SE) 69.5 (2.70) 74.8 (2.15) 70.3 (2.31) 74.2 (2.46) 71.1 (2.02) 75.7 (1.74)
Anti-hypertensive medication, % (SE) 80.6 (2.16) 80.0 (1.90) 82.0 (1.96) 87.4 (2.46) 92.4 (1.23){ 92.4 (1.11){
BP= Blood Pressure; SE = standard error; Values and significance testing controls for age and sex, body mass index, vascular co-morbidity and smoking (age controlled at
75, female sex, non-smoker, no co-morbidity and BMI = 28.8 – the English mean). Significance tests compare the medium and high SEP groups with the low within each
country.
{p,0.05.
doi:10.1371/journal.pone.0083705.t003
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pressure control. This may be especially relevant in a US sample
with no single insurance source, which is exposed to under-
insurance and co-payment [27]. Our data did not permit us to
determine which medications were prescribed (nor how many).
Therefore, we could not assess the appropriateness of prescribing
(including combination therapy).
Strengths & Limitations
Our study has potential limitations. We used patient-reported
diagnoses of hypertension. While this definition may underesti-
mate prevalence [5], we felt it more appropriate than one based on
blood pressure values, which will include undiagnosed cases. After
all, the health system is only able to manage disease when
diagnosed and recorded. Use of self-reporting may have influenced
our findings. Most notably, we may underestimate levels of
prescribing, although differences between countries are likely to be
minimal. We have data on only one aspect of hypertension
management; anti-hypertensive prescribing, however, this is a core
aspect of control, highlighted by clinical guidelines in both
countries. We did not have data on the class of antihypertensive
agent prescribed, or the number. These differences may contribute
to the cross-national differences in blood pressure control, and
may require further study. While hypertension is a common, high
burden disease and our study provides key insights related to its
management, it may not be appropriate to extrapolate findings to
other disease areas, particularly higher cost acute conditions. We
limited our study to white respondents in each country. This
allowed us to focus on national differences in health care insurance
and policies, without confounding from ethnically different
minority groups. This allows greater focus on the research
question, improves validity, but will limit the applicability of our
findings to the general population in both countries. Our data only
cover older adults, so findings may not be generalisable to all ages.
Finally, the survey contained missing data for outcomes and
covariates. The nested survey design, however, combined with the
weights, ensure those with complete data remain representative.
Impacts on policy and practice
Hypertension control in both countries remains suboptimal;
blood pressure is controlled to clinical targets in just over a half of
patients aged 65 years and over. Given the association between
blood pressure control and good health outcomes [34], and despite
an array of efficacious medications [3], further efforts are required
to improve the management of hypertension in both countries.
Chronic disease control may also be influenced by population
factors, including dietary behaviours and lifestyle [35]. Managing
Table 4. Blood pressure control and prescribing in hypertensive patients in US market-based v English NHS by socioeconomic-
position (aged 50-64 years).
England United States
Total Total Insured
Years of Education
Low Medium High Low Medium High Low Medium High
Systolic BP mean (SE) 136.9 (1.35) 131.3 (2.10)` 134.2 (1.46) 132.8 (1.42) 131.5 (1.70) 129.0 (1.45){ 131.2 (1.50) 130.6 (1.76) 128.0 (1.46)
Diastolic BP mean (SE) 81.9 (0.82) 81.0 (1.47) 81.1 (0.85) 84.5 (0.93) 85.0 (1.04) 84.9 (0.95) 83.4 (0.98) 84.3 (1.00) 84.0 (0.93)
BP ,140/90 mmHg, % (SE) 57.8 (4.17) 70.3 (6.52) 64.6 (4.30) 59.3 (4.18) 59.7 (4.80) 68.0 (4.20) 63.2 (4.46) 62.5 (5.00) 70.1 (4.28)
BP ,150/90 mmHg, % (SE) 71.9 (3.89) 76.6 (6.15) 78.2 (3.71) 67.4 (4.09) 70.2 (4.61) 70.9 (4.21) 71.7 (4.22) 72.4 (4.64) 73.8 (4.22)
Anti-hypertensive medication, % (SE) 53.4 (4.32) 58.0 (7.06) 61.3 (4.58) 78.4 (3.89) 77.4 (4.23) 84.4 (3.50) 84.3 (3.87) 80.2 (4.01) 87.2 (3.32)
Income
Low Medium High Low Medium High Low Medium High
Systolic BP mean (SE) 134.0 (1.62) 136.3 (1.61) 135.7 (1.35) 135.5 (1.87) 129.5 (1.63)` 130.9 (1.22){ 132.6 (2.09) 128.2 (1.70) 130.2 (1.24)
Diastolic BP mean (SE) 81.4 (0.97) 81.7 (0.97) 81.5 (0.82) 86.5 (1.18) 83.3 (1.09){ 85.1 (0.75) 84.4 (1.32) 82.3 (1.13) 84.4 (0.73)
BP ,140/90 mmHg, % (SE) 62.6 (4.95) 58.1 (4.77) 62.6 (4.01) 54.9 (5.67) 66.6 (4.42){ 62.2 (3.60) 62.4 (6.38) 69.1 (4.58) 64.5 (3.73)
BP ,150/90 mmHg, % (SE) 75.3 (4.52) 74.2 (4.24) 74.2 (3.68) 62.5 (5.82) 75.8 (3.94){ 68.2 (3.55) 71.4 (6.25) 78.6 (3.91) 70.5 (3.61)
Anti-hypertensive medication, % (SE) 51.7 (5.41) 61.6 (4.59) 55.6 (4.35) 74.9 (5.38) 83.8 (3.77) 80.0 (3.08) 81.4 (5.34) 89.3 (3.25) 82.6 (3.06)
Wealth
Low Medium High Low Medium High Low Medium High
Systolic BP mean (SE) 133.7 (1.59) 135.9 (1.45) 136.4 (1.49) 133.8 (1.62) 131.9 (1.58) 128.6 (1.29){ 131.6 (1.73) 130.7 (1.65) 128.2 (1.33)
Diastolic BP mean (SE) 81.1 (0.95) 81.0 (0.87) 82.2 (0.90) 85.6 (1.14) 85.5 (0.95) 83.5 (0.80) 83.9 (1.18) 84.6 (0.98) 83.2 (0.81)
BP ,140/90 mmHg, % (SE) 63.5 (4.61) 59.7 (4.61) 60.9 (4.37) 55.2 (4.74) 57.6 (4.39) 71.7 (3.95)` 60.7 (5.07) 60.4 (4.67) 72.5 (4.08){
BP ,150/90 mmHg, % (SE) 75.1 (4.34) 74.4 (4.04) 74.0 (3.96) 64.3 (4.84) 64.2 (4.36) 78.0 (3.51)` 69.3 (4.99) 67.6 (4.57) 78.9 (3.56)
Anti-hypertensive medication, % (SE) 57.1 (5.04) 59.3 (4.64) 53.8 (4.53) 71.2 (5.18) 80.5 (3.67) 86.0 (2.83)` 81.6 (4.70) 81.6 (3.86) 87.7 (2.73)
BP = Blood Pressure; SE = standard error; Values and significance testing control for age and sex, body mass index, vascular co-morbidity and smoking (age controlled at
57, female sex, non-smoker, no co-morbidity and BMI = 30.2 – the English mean in the age group. Significance tests compare the medium and high SEP groups with the
low within each country.
{p,0.05.
`p,0.01.
doi:10.1371/journal.pone.0083705.t004
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underlying causes of disease and poor control warrant greater
attention [36].
The English and American health care systems differ in many
ways, including the provision of universal coverage and overall
levels of expenditure. Our study demonstrates that hypertension
control in England matches that in the US in a sample without
universal health insurance, despite the evidence elsewhere of lower
overall expenditure. The two study samples covered by universal
health insurance had the lowest disparities in hypertension control,
and in one – in England – were entirely absent. The ACA’s vision
of improving access to healthcare may promote equitable care.
Interestingly, while there were no indications of health care
disparities in the English system, some persisted in the US, even
when patients had insurance (either private insurance for patients
under 65 years or Medicare for older patients). The introduction
of universal coverage at the age of 65 years may not eliminate
disparities that become too entrenched; although may reduce
them. Again, the ACA’s expansion of Medicare and its individual
mandate – expanding private insurance coverage – may increase
equity. Alternately, other country-level differences, such as the
underlying structures or subtle challenges to care access, including
co-payment, may perpetuate disparities: If so, further system-level
changes may be required, which the ACA only begins to tackle.
Conclusions
Characteristics of both a single-payer health service and
universal health insurance coverage may facilitate high-quality,
equitable treatment. The expansion of Medicaid eligibility and
widening private insurance coverage under the ACA, indeed the
promotion of universal health coverage globally [37], may
encourage equitable management of chronic conditions such as
hypertension. Unlike disparities in disease prevalence which
appear influenced by, amongst other things, wider redistributive
social policy and the prevalence of disease risk factors [5,6], our
findings suggest disparities in hypertension control may be more
closely linked to health system structure, notably access to care
through insurance. Although our study demonstrates that not all
kinds of ‘‘universal’’ health insurance are alike, it supports the
ambition that expanding health insurance may reduce health
disparities.
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